PRN: Non-Invasive Cancer Diagnostics Market, 2015 - 2030 - Market Is Anticipated to Grow Aggressively at a Healthy Annual Growth Rate of 44%

27/gen/2016 17:11:06 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Non-Invasive Cancer Diagnostics Market, 2015 - 2030 - Market Is Anticipated to Grow Aggressively at a Healthy Annual Growth Rate of 44%


DUBLIN, Jan. 27, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Non-Invasive Cancer Diagnostics Market, 2015 - 2030" report to their offering.

The Non-Invasive Cancer Diagnostics Market, 2015-2030' report provides an extensive study on liquid biopsy kits/assays that are either commercialised or under development for the diagnosis of different types of cancer. Liquid biopsy primarily focuses on the detection, isolation and characterisation of biomarkers from circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw.

The market is characterised by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or molecular characterisation/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, patient and recurrence monitoring. It is important to stress that even though liquid biopsy has still not made a strong foothold in the field of oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the near future.

In addition to liquid biopsy, there are several other novel and promising non-invasive diagnostics being developed for the diagnosis and prognosis of cancer. However, these tests are only indicative of the disease and may require further validation through more robust diagnostic methods such as biopsy. These tests retrieve the test sample non-invasively and use innovative techniques to screen for the desired parameters indicative of the disease with a moderate level of accuracy. Some of these are designed to be used at home by the patient itself.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives outlined for this report is to understand the future potential of the market.

This is done by analysing:

- The global burden of cancer in terms of incidence and prevalence of different cancer indications across different geographies. - The overall landscape of liquid biopsies and other novel diagnostic tests with respect to the type of analysis (CTCs/ctNA/exosomes), test sample source (blood/urine/others) and indications. - The likely global evolution of the liquid biopsy market taking into account initial diagnosis, recurrence monitoring and patient monitoring. - Contribution of other novel diagnostic tests in the non-invasive cancer diagnostics market and the market opportunity of the key indications influencing the overall growth.

Example Highlights:

- We have identified over 50 liquid biopsy tests; some of these are commercialised and the rest are currently under development. Of these, 50% tests are based on the identification of disease biomarkers in ctDNA of the test sample. Nearly 37% of the tests are based on the enumeration/analysis of CTCs in the sample and the remaining 13% validate the presence of the disease from the information obtained from exosomes.

- Several companies are developing systems and instruments to support the detection, isolation and characterisation of rare cells. Examples include (in no specific order) the Parsortix System by ANGLE, ScreenCell® Isolation Devices by ScreenCell, ApoStream System by ApoCell, ClearCell FX® System by ClearbridgeBioMedics and iCellate® Instrument by iCellate Medical.

- Firms have also taken initiatives and entered into collaborations to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between Tokai Pharmaceuticals and Qiagen, AstraZeneca and Qiagen, SysmexInostics and Bayer HealthCare.

- In addition to liquid biopsy, we have identified close to 40 other non-invasive cancer diagnostics that are used for screening, diagnosis, prognosis and patient monitoring; these include techniques based on molecular imaging, advanced methods of detecting clinically significant biomarkers and identification of nucleosomal levels.

- Primarily driven by liquid biopsy, the non-invasive cancer diagnostics market is anticipated to grow aggressively ata healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Concept Of Non-Invasive Cancer Screening And Diagnostics

5. Market Overview 

6. Liquid Biopsy: Detailed Outlook

7. Other Novel Non-Invasive Technologies

8. Market Sizing And Forecast

9. Company Profiles

- A&G Pharmaceutical

- Accelerate Brain Cancer Cure

- AcousysBiodevices

- Addario Lung Cancer Medical Institute

- Admera Health

- AdnaGen

- Affymetrix

- Agena Bioscience

- Almac Group

- America's Choice Provider Network

- American Lung Association

- Angle plc

- Anixa Diagnostics Corporation

- ApoCell

- ARUP Laboratories

- Astellas Pharma

- AstraZeneca

- Astute Medical

- Aviva Biosciences

- Barts Cancer Institute

- Bayer Healthcare

- BC Cancer Agency

- BGI Tech Solutions

- Biocartis

- Biocept

- Biodesix

- BioFluidica

- bioMérieux

- Biosense Medical

- Biotype Diagnostics

- BioView

- Boreal Genomics

- Brigham and Women's Hospital

- Canopus Bioscience

- Catholic Health Initiatives Center

- Clarient

- ClearbridgeBioMedics

- Clovis Oncology

- CollabRx

- Columbia University

- Comprehensive Cancer Center


- CreatvMicroTech

- Cubist Pharmaceuticals

- CynvenioBiosystems

- CytoTrack

- CytoLumina Technologies

- Dana Farber Cancer Institute

- Datar Generics

- Denovo Sciences

- DermTech

- DiagnoCure

- Diagnologix

- Digene Corporation

- Drug Response Dx

- EKF Molecular Diagnostics

- Eli Lilly

- Epic Sciences

- Epigenomics

- European Medical Network for Translational Research in Ovarian Cancer

- Exact Sciences

- Exosome Diagnostics

- Exosomics Siena

- Fairview Health Services

- FedMed

- Flatiron Health

- Fluxion Biosciences

- Foundation Medicine

- Fraunhofer Institute for Cell Therapy and Immunology

- Genomic Health

- Genoptix

- Gensignia

- GlaxoSmithKline

- Guangdong Medical College

- Guardant Health

- HainLifescience

- HansaBioMed

- Healthscope Pathology

- Hitachi High-Technologies

- iCellate Medical

- Illumina

- Incyte Genomics

- Inivata

- Insight Genetics

- Ipsen

- Ironwood Pharmaceuticals

- IVDiagnostics

- Janssen Diagnostics

- OHSU Knight Cancer Institute

- Labcorp

- London Health Sciences Centre

- Louisiana State University

- Massachusetts General Hospital

- Mayo Clinic

- Mayo Medical Laboratory Network

- MD Anderson Cancer Center

- MDx Health

- Medical University of Vienna

- MELA Sciences

- Merck Serono


- MolecularMD

- Molecular Pathology Laboratory Network

- Natera

- National Cancer Institute

- NeoGenomics Laboratory

- Novartis

- Novigenix

- Ortho Biotech Oncology Research & Development

- Pacific Edge

- Palex Medical

- Pathway Genomics

- PathQC

- Personal Genome Diagnostics

- Promega Corporation

- Prostate Cancer Foundation

- Qiagen

- Quanterix

- Quest Diagnostics

- RainDance Technologies

- Rarecells Diagnostics

- RareCyte

- Roche

- Rosetta Genomics

- Roswell Park Cancer Institute

- Royal Philips Electronics

- Rutgers New Jersey Medical School

- SAIC-Frederick

- Sarah Cannon Research Institute

- ScheBo

- ScreenCell

- Siemens

- Sequenom

- Shimadzu

- Shuwen Biotech

- Signal Genetics

- Signature Diagnostics

- Silicon Biosystems


- Skyline Diagnostics

- Southern California Permanente Medical Group

- SRI International

- StableBody Technologies

- Stiefel Laboratories

- Strand Life Sciences

- SysmexInostics

- Tan TockSeng Hospital

- Targeted Diagnostics & Therapeutics

- Technion-Israel Institute of Technology

- The Valld'Hebron Institute of Oncology

- Thermo Fisher Scientific

- Thomas Jefferson University

- Tokai Pharmaceuticals

- Transgenomic

- Trovagene

- Tumour Bank Ovarian Cancer Network

- University of California

- University of Dusseldorf

- University of Michigan

- University of Nijmegen

- University of Southern California

- University of Texas

- Uppsala BIO

- Vancouver Prostate Centre

- Veolia Environnement

- Veracyte

- Veridex

- Viatar CTC Solutions

- Virginia Commonwealth University

- Vitatex

- VolitionRx

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,



blog comments powered by Disqus è un servizio offerto da Factotum Srl